News | April 24, 2026
Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The company allocated €56 million to research and development for next-generation line solutions
The facility is expected to become operational by FY2028-29
The company’s EBITDA margin remained resilient above 20%
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Subscribe To Our Newsletter & Stay Updated
